JGC
JANX icon

J. Goldman & Co’s Janux Therapeutics JANX Stock Holding History

J. Goldman & Co’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-5,400
Closed -$245K – 545
2024
Q3 		$245K Hold
5,400
– – 0.01% 406
2024
Q2 		$226K Buy
+5,400
New +$254K 0.01% 401

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

J. Goldman & Co's JANX Position: Q4 2024 in Review

J. Goldman & Co sold out of Janux Therapeutics (JANX) in Q4 2024, closing a stake of 5,400 shares — an estimated $245K sold.

J. Goldman & Co first reported a position in JANX in Q2 2024 and held it in 2 quarters. The position peaked at $245K in Q3 2024. 216 funds tracked by Wall St. Rank hold JANX as of Q4 2024.

  • J. Goldman & Co reported no remaining Janux Therapeutics position as of Q4 2024 after selling out during the quarter.
  • J. Goldman & Co sold 5,400 Janux Therapeutics shares in Q4 2024, an estimated $245K.
  • J. Goldman & Co first reported a position in Janux Therapeutics in Q2 2024 and held it in 2 quarters.
  • J. Goldman & Co's Janux Therapeutics position peaked at $245K in Q3 2024.
  • 216 funds tracked by Wall St. Rank held Janux Therapeutics as of Q4 2024.

Based on J. Goldman & Co's 13F filing for Q4 2024, filed 14 Feb 2025.